A side-by-side regulatory comparison of three key LATAM markets — helping sponsors choose the right country for their clinical trial phase and objectives.
August 14, 2026
16
min read
By
bioaccess® Editorial Team
clinical trial regulations comparison
Venezuela vs Colombia clinical trials
Latin America clinical trial comparison
**Key Takeaways**
- • Venezuela: Lowest operating costs, treatment-naïve populations, INHRR regulatory pathway
- • Colombia: Established FIH track record, INVIMA regulatory authority, study-specific startup
- • Argentina: ICH member, ANMAT oversight, sophisticated regulatory infrastructure, a timeline that varies by study (we confirm it per protocol)
- • Multi-country: bioaccess® supports trials across all three simultaneously
- • FDA acceptance: Data from all three countries accepted under ICH-GCP
**The short answer**
Venezuela (INHRR) has the lowest operating costs of the three in our experience, with treatment-naïve populations and an Varies by study; we confirm per protocol startup timeline. Colombia (INVIMA) brings an established FIH track record with Varies by study; we confirm per protocol startups, while Argentina (ANMAT), a full ICH member, offers sophisticated infrastructure at Varies by study; we confirm per protocol. Clinical data from all three countries is accepted by the FDA under ICH-GCP.
Why compare Venezuela, Colombia, and Argentina?
Venezuela, Colombia, and Argentina represent three distinct but complementary clinical trial markets in Latin America. Each country offers unique advantages, and understanding the regulatory differences helps sponsors make informed decisions about where to conduct their studies.
bioaccess® operates in all three countries and helps sponsors choose the optimal market — or multi-country strategy — based on their therapeutic area, trial phase, budget, and timeline requirements.
How do the regulatory authorities compare?
| Feature | Venezuela | Colombia | Argentina |
|---|---|---|---|
| Regulatory Authority | INHRR | INVIMA | ANMAT/ANEFITS |
| Ministry | MPPS | Min. Health | Min. Health |
| ICH Member | No (follows ICH-GCP) | No (follows ICH-GCP) | Yes (full member) |
| CTA Review Type | Scientific + administrative | Scientific + administrative | Parallel review (ANEFITS) |
| Device Registration | SACS (varies by study; we confirm per protocol) | INVIMA | ANMAT |
| International Recognition | PAHO aligned | PAHO aligned | ICH, IMDRF |
For a deeper look at Venezuela’s pathway, see our complete INHRR approval guide; Colombia’s process is covered in our INVIMA approval guide.
How do approval timelines compare?
| Phase | Venezuela | Colombia | Argentina |
|---|---|---|---|
| CRO engagement to CTA submission | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol |
| Regulatory review | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol (ANEFITS) |
| Ethics review | Varies by study; we confirm per protocol (parallel) | Varies by study; we confirm per protocol (parallel) | Varies by study; we confirm per protocol (parallel) |
| Site activation to FPI | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol |
| Total startup | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol | Varies by study; we confirm per protocol |
Venezuela’s study-specific startup breaks down into six phases in our detailed timeline guide.
How do costs compare across the three markets?
| Cost Factor | Venezuela | Colombia | Argentina |
|---|---|---|---|
| Regulatory fees | ~VES 52,612 | ~$3,000-$5,000 USD | ~$2,000-$4,000 USD |
| Overall cost ranking | Lowest | Mid-range | Mid-range |
How do ethics committee requirements compare?
- Venezuela: Institutional ethics committees, PAHO standards, 4-8 week review
- Colombia: INVIMA-supervised institutional ethics committees, study-specific review
- Argentina: Provincial ethics committees + ANEFITS parallel review, a timeline that varies by study (we confirm it per protocol)
Which country for which trial phase?
| Trial Phase | Best Fit Country | Why |
|---|---|---|
| First-in-Human (FIH) | Venezuela or Colombia | Lowest cost (VEN), established FIH track record (COL) |
| Early Feasibility Study | Colombia or Argentina | Regulatory familiarity with IDE-like pathways |
| Phase II Proof of Concept | Colombia or Argentina | Larger investigator networks, enrollment speed |
| Phase III Pivotal | Argentina or Colombia | ICH membership (ARG), diverse demographics |
| Market Access / Registration | Venezuela | SACS study-specific device registration |
How should sponsors design a multi-country LATAM strategy?
Many sponsors benefit from a multi-country approach that leverages the unique advantages of each market. bioaccess® designs multi-country strategies that may include:
- FIH in Venezuela (lowest cost, treatment-naïve populations)
- Expansion to Colombia for additional enrollment and investigator diversity
- Argentina for ICH-standard regulatory pathway and pivotal trial support
- Multi-country data pooling for stronger FDA submission packages
- Simultaneous regulatory submissions across multiple countries
What is bioaccess®'s multi-country advantage?
bioaccess® is uniquely positioned to support multi-country clinical trials across Venezuela, Colombia, Argentina, and other LATAM markets. Our single-vendor approach provides:
- Unified project management across all countries
- Harmonized data collection and safety reporting
- Consistent GCP compliance and quality standards
- Single point of contact for sponsors
- Integrated regulatory strategy across multiple authorities
- Cost-efficient multi-country operations
**Need help choosing the right LATAM country?**
Contact bioaccess® for a complimentary country selection assessment based on your protocol and objectives. Or explore our CRO comparison page to see how we stack up.
Frequently asked questions
Get your FIH roadmap for Latin America
bioaccess® helps you choose the right country and strategy for your clinical trial.